Efficiacy of regorafenib in patients with chemotheraphy-resistant metastatic colorectal cancer

Colorectal cancer is common and deadly disease. Acording to the 2018 global cancer statistics data, it is the third most common cancer regardless of gender (10,2%). Again, according to the same data, the mortality rate is second after lung cancer. Most patients with metastatic colorectal cancer cannot be cured, but a subset of patients with liver and / or lung isolated metastatic disease, local recurrence or limited intraabdominal disease can be treated surgically.The past 10 to 15 years have discussed significant advances in the treatment of metastatic colorectal cancer. From the early 90s, Fluorourasil is the most effective agent alone, extending its survival to 11-12 months. Recently, the average survival is about three years, and five-year survival rates of only 20% of patients treated with chemotherapy have been reported. These developments led to the opening of new active agents containing traditional cytotoxic agents other than (Fluorourasil) FU and biological agents targeting angiogenesis and Epidermal Growth Factor Receptor (EGFR). Regorafenib is an orally active inhibitor of angiogenic tyrosine kinases (including (Vascular Endothelial Growth Factor Receptor) VEGF receptors), as well as other receptor and intracellular kinases. Regorafenib is used for the treatment of resistant metastatic colorectal cancer, previously treated with fluoropyrimidine, oxaliplatin- and irinotecan-based chemotherapy. In our study, patients who were followed up with a diagnosis of metastatic colorectal cancer and who received a multi-kinase inhibitor Regorafenib due to progression after standard systemic treatments ; treatment response, tolerance, drug side effects, progression-free survival and overall survival were evaluated retrospectively. Regorafenib, which is used in rescue treatment in patients receiving multiple-choice chemotherapy, has been shown to be effective on progression-free survival and overall survival. Key words: Colorectal Cancer, Regorafenib, Metastasis, Chemotheraphy